SynthesisBMC nephrology2026
Sexual dysfunction and effect on quality of life in chronic kidney disease: a systematic review and meta-analysis.
Synthesis in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSexual dysfunction in chronic kidney disease (CKD) is frequently underrecognized and underreported worldwide, despite its well-established association with depression and reduced quality of life (QoL). This study estimated the pooled global prevalence of sexual dysfunction among individuals with CKD and evaluated its impact on psychosocial well-being.
methodsA systematic review and meta-analysis of published studies examining sexual dysfunction in CKD was conducted following PRISMA 2020 guidelines (PROSPERO: CRD42024508777). Pooled prevalence estimates were calculated using a DerSimonian-Laird random-effects model with Freeman-Tukey double arcsine transformation, and correlation coefficients were pooled following Fisher's Z transformation.
resultsForty-four eligible studies, involving 10,672 participants from 18 countries, were included. The overall pooled prevalence of sexual dysfunction was 71.2% (95% CI: 65.9-76.3%, I²= 96.8%), with no significant difference across geographical regions (p = 0.87) or between males (71.5%, 95% CI: 65.5-77.3%) and females (67.3%, 95% CI: 52.6-80.5%) (p = 0.61). Prevalence was significantly higher among patients on hemodialysis (77.6%) and those in predialysis stage (76.7%) compared with post-kidney transplant recipients (56.9%), with a significant difference across patient groups (p = 0.01). Sexual dysfunction was significantly correlated with poorer mental (r ≈ 0.36, 95% CI: 0.27-0.45, p < 0.001) and physical (r ≈ 0.39, 95% CI: 0.29-0.48, p < 0.001) health-related quality of life, as well as greater depression severity as measured by the IIEF (r = -0.34, p < 0.001) and FSFI (r = -0.42, p < 0.001). No significant publication bias was observed on Begg's test (p = 0.48) or Egger's test (p = 0.16).
conclusionSexual dysfunction is highly prevalent among individuals with CKD, affecting more than two-thirds of patients and varying by treatment modality, with lower prevalence observed after kidney transplantation. It is significantly associated with poorer quality of life and depression severity. These findings underscore the need for routine screening and integrated psychological and sexual health interventions in CKD care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.